Individual Study / PROPSPER

Prospective Study of Pravastatin in the Elderly at Risk

Prospective Study of Pravastatin in the Elderly at Risk

Initiatives -
To investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option. To examine the hypothesis that pravastatin, at a dose of 40 mg/day, will reduce the risk of cardiovascular and cerebrovascular events in elderly subjects with vascular disease or at high risk of developing vascular disease. *Note: All published information has been collected from the article referenced in the Marker Paper box below. Therefore, there may be variations with more advanced versions of the study.*


Investigators Contacts
  • Dr. Prof. Ian Ford
    University of Glasgow


Study design
Clinical trial cohort
Follow Up
Follow-up visits every 3 months for a minimim of 3 years.

Marker Paper

Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, Ford I, Jukema JW, Hyland M, Gaw A, Lagaay AM, Perry IJ, Macfarlane PW, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RG, Twomey C, Stott DJ. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol. 1999 Nov 15;84(10):1192-7. doi: 10.1016/s0002-9149(99)00533-0.

PUBMED 10569329


Sources of Recruitment
  • Individuals

Number of participants

Number of participants
Number of participants with biosamples
Supplementary Information
Cohort of men and women (70 to 82 years old)


Availability of data and biosamples